ABSTRACT
Signal transducers and activators of transcription (STATs) play a central role in cytokine signaling. Activating and repressing gene transcription is a dynamic process involving chromatin remodeling by histone acetylases and deacetylases, yet the role of this process in STAT-dependent transcription remains largely unknown. In a search for STAT5-interacting proteins by yeast two-hybrid screening, we identified the nuclear receptor co-repressor SMRT (silencing mediator for retinoic acid receptor and thyroid hormone receptor) as a potential STAT5-binding partner. SMRT binds to both STAT5A and 5B, and strongly repressed STAT5-dependent transcription in vitro. SMRT binds to the N-terminal coiled-coil domain of STAT5 and a mutation within this region previously found to render STAT5 hyperactive in response to cytokines abolished the interaction with SMRT. Overexpression of SMRT suppressed the induction of STAT5 target genes by interleukin-3, whereas the histone deacetylase inhibitor trichostatin A effectively enhanced and prolonged their expression. Together, these findings illuminate the potential role of SMRT in down-regulating STAT5 activity, with a consequent reduction of STAT5 target gene expression.
Subject(s)
DNA-Binding Proteins/genetics , DNA-Binding Proteins/metabolism , Gene Expression Regulation , Milk Proteins , Repressor Proteins/genetics , Repressor Proteins/metabolism , Trans-Activators/genetics , Trans-Activators/metabolism , Transcription, Genetic , Blotting, Northern , Blotting, Western , Cell Line , Cytokines/metabolism , Down-Regulation , Electrophoresis, Polyacrylamide Gel , Humans , Interleukin-3/metabolism , Luciferases/metabolism , Mutation , Nuclear Receptor Co-Repressor 2 , Plasmids/metabolism , Point Mutation , Precipitin Tests , Protein Binding , Protein Structure, Tertiary , STAT5 Transcription Factor , Signal Transduction , Transfection , Tumor Suppressor Proteins , Two-Hybrid System TechniquesABSTRACT
Our recent studies using targeted gene disruption have shown that defects in phospholipase Cgamma2 (PLCgamma2) result in a B-cell abnormality that is very similar to that seen in Btk-deficient mice. Null mutations in either PLCG2 or BTK are associated with decreased numbers of mature B cells, failure to make antibodies to some T cell-independent antigens and the absence of CD5+ peritoneal B cells. Mutations in BTK in humans cause a more severe defect in B-cell development characterized by almost complete absence of B cells in the peripheral circulation, profound hypogammaglobulinemia and an inability to produce antibodies to any antigens. However, not all patients with severe defects in B-cell development have mutations in BTK or the components of the B-cell signal transduction complex. To explore the possibility that some patients with defects in B-cell development of unknown etiology might have mutations in PLCG2, we determined the genomic structure of this gene and established conditions to analyze the 32 exons of the gene and the flanking sequences by single-strand conformation polymorphism. Although 24 polymorphic variants of this gene were found in 35 patients, we did not identify any alterations that were likely to be the cause of disease.
Subject(s)
B-Lymphocytes/immunology , Genetic Variation , Immunologic Deficiency Syndromes/etiology , Immunologic Deficiency Syndromes/genetics , Isoenzymes/genetics , Type C Phospholipases/genetics , Agammaglobulinemia/genetics , Amino Acid Sequence , Base Sequence , Exons , Female , Genome, Human , Humans , Introns , Male , Molecular Sequence Data , Phospholipase C gamma , Polymorphism, Single-Stranded Conformational , Sequence Homology, Amino Acid , Sequence Homology, Nucleic AcidABSTRACT
Cellular trafficking of growth factor receptors, including cross-talk among receptors at the cell surface, may be important for signal transduction in normal hematopoietic cells. To test this idea, the signaling domain of Mpl (the thrombopoietin receptor) was targeted to the plasma membrane, or to the cytoplasm of murine marrow cells, and the ability of the cells to proliferate and differentiate in response to Mpl dimerized at the plasma membrane or free in the cytoplasm was assessed. Constructs encoding the signaling domain of Mpl linked to an FK506 binding protein domain (to permit dimerization by the membrane-permeable ligand AP20187) with or without a myristylation sequence (to target the receptor to the plasma membrane) and a hemagglutinin epitope tag were generated and introduced into murine marrow cells using a murine stem cell virus (MSCV)-based retroviral vector. Both populations of transduced marrow cells proliferated in Iscoves modified Dulbecco medium-10% FCS-100 nM AP20187 without exogenous growth factors for more than 100 days and achieved greater than a 10(7)-fold expansion of cells by day 50 (n = 4 transductions). Growth was dimerizer dependent, and myeloid, erythroid, and megakaryocytic progenitors were generated. Activation of Mpl either at the plasma membrane or in the cytoplasm allowed for the terminal maturation of transduced progenitor cells. Introduction of membrane-targeted or cytoplasmic Mpl into fetal liver cells from homozygous JAK2 knock-out mice or wild-type littermates demonstrated that both forms of Mpl require JAK2 for signaling. These data show that the activation of Mpl independent of its normal plasma membrane location can support production of the full range of normal hematopoietic progenitor cells in vitro.
Subject(s)
Cell Membrane/metabolism , Hematopoietic Stem Cells/drug effects , Milk Proteins , Neoplasm Proteins , Proto-Oncogene Proteins/physiology , Receptors, Cytokine , Animals , Bone Marrow Cells/cytology , Bone Marrow Cells/drug effects , Cell Differentiation/drug effects , Cell Division/drug effects , Cell Line , Cell Membrane/chemistry , Cytoplasm/chemistry , DNA-Binding Proteins/pharmacology , DNA-Binding Proteins/physiology , Dimerization , Hematopoietic Stem Cells/cytology , Janus Kinase 2 , Mice , Microscopy, Fluorescence , Protein Transport , Protein-Tyrosine Kinases/pharmacology , Protein-Tyrosine Kinases/physiology , Proto-Oncogene Proteins/pharmacology , Receptors, Thrombopoietin , STAT5 Transcription Factor , Signal Transduction , Trans-Activators/pharmacology , Trans-Activators/physiologyABSTRACT
Granulocyte colony-stimulating factor (G-CSF) is a major cytokine that regulates proliferation and differentiation of myeloid cells, although the underlying mechanisms by which G-CSF controls myeloid differentiation are largely unknown. Differentiation of hematopoietic cells is regulated by lineage-specific transcription factors, and gene-targeting studies previously revealed the critical roles of CCAAT/enhancer-binding protein (C/EBP) alpha and C/EBP epsilon, respectively, in the early and mid-late stages of granulocyte differentiation. The expression of C/EBP epsilon in 32Dcl3 cells and FDCP1 cells expressing mutant G-CSF receptors was examined and it was found that G-CSF up-regulates C/EBP epsilon. The signal for this expression required the region containing the first tyrosine residue of G-CSF receptor. Dominant-negative signal transducers and activators of transcription 3 blocked G-CSF--induced granulocytic differentiation in 32D cells but did not block induction of C/EBP epsilon, indicating that these proteins work in different pathways. It was also found that overexpression of C/EBP epsilon greatly facilitated granulocytic differentiation by G-CSF and, surprisingly, that expression of C/EBP epsilon alone was sufficient to make cells differentiate into morphologically and functionally mature granulocytes. Overexpression of c-myc inhibits differentiation of hematopoietic cells, but the molecular mechanisms of this inhibition are not fully understood. In 32Dcl3 cells overexpressing c-myc that do not differentiate by means of G-CSF, induction of C/EBP epsilon is completely abrogated. Ectopic expression of C/EBP epsilon in these cells induced features of differentiation, including changes in nuclear morphologic characteristics and the appearance of granules. These data show that C/EBP epsilon constitutes a rate-limiting step in G-CSF-regulated granulocyte differentiation and that c-myc antagonizes G-CSF-induced myeloid differentiation, at least partly by suppressing induction of C/EBP epsilon. (Blood. 2001;98:897-905)
Subject(s)
CCAAT-Binding Factor/pharmacology , CCAAT-Enhancer-Binding Proteins/pharmacology , Granulocyte Colony-Stimulating Factor/pharmacology , Myeloid Cells/cytology , Animals , CCAAT-Enhancer-Binding Proteins/drug effects , CCAAT-Enhancer-Binding Proteins/physiology , Cell Differentiation/drug effects , Cell Division/drug effects , Cell Line , DNA-Binding Proteins/pharmacology , Drug Interactions , Granulocytes/cytology , Granulocytes/drug effects , Mice , Myeloid Cells/drug effects , Proto-Oncogene Proteins c-myc/pharmacology , STAT3 Transcription Factor , Trans-Activators/pharmacology , Up-Regulation/drug effectsABSTRACT
The erythropoietin receptor (EpoR) is required for the proliferation and survival of committed erythroid lineage cells. Previous studies have utilized receptor mutations to show the requirement for the distal half of the cytoplasmic domain of the EpoR and receptor tyrosines for activation of signaling pathways potentially critical to Epo function. To extend these studies to in vivo erythropoiesis, we have created two mutant strains of mice. One strain (H) contains a truncation of the distal half of the cytoplasmic domain, while the second strain (HM) contains the same truncation as well as the mutation of the residual tyrosine (Y(343)) to a phenylalanine. Strikingly, both strains of mice are viable, with only slight alterations in constitutive erythropoiesis or in in vitro assays of red cell lineage function. Challenging H mutant mice with continuous injections of Epo results in an erythrocytosis that is not seen in HM mice. The results demonstrate that neither the distal region nor receptor tyrosines are essential for in vivo EpoR function, but contribute to receptor function in a subtle manner.
Subject(s)
Erythropoiesis/physiology , Protein-Tyrosine Kinases/metabolism , Proto-Oncogene Proteins , Receptors, Erythropoietin/physiology , Animals , Binding Sites , Janus Kinase 2 , Mice , Mice, Inbred C3H , Mice, Inbred C57BL , Receptors, Erythropoietin/genetics , Receptors, Erythropoietin/metabolismABSTRACT
Gadd45gamma, a family member of the growth arrest and DNA damage-inducible gene family 45 (Gadd45), is strongly induced by interleukin-2 (IL-2) in peripheral T cells. While in most tissues all Gadd45 family members are expressed, Gadd45gamma is the only member that is induced by IL-2. Here we show that the IL-2-induced expression of Gadd45gamma is dependent on a signaling pathway mediated by the tyrosine kinase Jak3 and the transcription factors Stat5a and Stat5b (signal transducer and activator of transcription). Previous studies with ectopically overexpressed Gadd45gamma in various cell lines implicated its function in negative growth control. To analyze the physiological role of Gadd45gamma we used homologous recombination to generate mice lacking Gadd45gamma. Gadd45gamma-deficient mice develop normally, are indistinguishable from their littermates, and are fertile. Furthermore, hematopoiesis in mice lacking Gadd45gamma is not impaired and Gadd45gamma-deficient T lymphocytes show normal responses to IL-2. These data demonstrate that Gadd45gamma is not essential for normal mouse development and hematopoiesis, possibly due to functional redundancy among the Gadd45 family members. Gadd45gamma is also dispensable for IL-2-induced T-cell proliferation.
Subject(s)
Milk Proteins , Proteins/physiology , T-Lymphocytes/cytology , Animals , Bone Marrow Cells/drug effects , Bone Marrow Cells/metabolism , Cell Cycle , Cell Division , Cells, Cultured , DNA-Binding Proteins/metabolism , Embryonic and Fetal Development , Interleukin-2/pharmacology , Intracellular Signaling Peptides and Proteins , JNK Mitogen-Activated Protein Kinases , Janus Kinase 3 , Mice , Mice, Inbred C57BL , Mice, Knockout , Mitogen-Activated Protein Kinases/metabolism , Protein-Tyrosine Kinases/metabolism , Proteins/genetics , STAT5 Transcription Factor , T-Lymphocytes/drug effects , Trans-Activators/metabolism , Transcription, Genetic , GADD45 ProteinsABSTRACT
During the past few years studies from several laboratories have utilized gene disruption approaches to define the function of members of the Stat family of transcription factors. The results have demonstrated that each family member has unique, critical, non-redundant functions in signal transduction through members of the cytokine receptor superfamily. Many of the family members mediate functions associated with innate or acquired immunity. With the availability of mice deficient in one or more of the Stats, critical experiments are possible to evaluate the roles of Stat signal transduction pathways in cellular transformation as well as evaluating their specific roles in a range of cellular responses to cytokines.
Subject(s)
DNA-Binding Proteins/physiology , Milk Proteins , Receptors, Cytokine/physiology , Signal Transduction , Trans-Activators/physiology , Animals , DNA-Binding Proteins/genetics , Humans , STAT1 Transcription Factor , STAT2 Transcription Factor , STAT3 Transcription Factor , STAT4 Transcription Factor , STAT5 Transcription Factor , STAT6 Transcription Factor , Trans-Activators/geneticsABSTRACT
The cytokines IL-4 and IL-13 inhibit the production of NO from activated macrophages through an unresolved molecular mechanism. We show here that IL-4 and IL-13 regulate NO production through depletion of arginine, the substrate of inducible NO synthase (iNOS). Inhibition of NO production from murine macrophages stimulated with LPS and IFN-gamma by IL-4 or IL-13 was dependent on Stat6, cell density in the cultures, and pretreatment for at least 6 h. IL-4/IL-13 did not interfere with the expression or activity of iNOS but up-regulated arginase I (the liver isoform of arginase) in a Stat6-dependent manner. Addition of exogenous arginine completely restored NO production in IL-4-treated macrophages. Furthermore, impaired killing of the intracellular pathogen Toxoplasma gondii in IL-4-treated macrophages was overcome by supplementing L-arginine. The simple system of regulated substrate competition between arginase and iNOS has implications for understanding the physiological regulation of NO production.
Subject(s)
Nitric Oxide/biosynthesis , Trans-Activators/physiology , Animals , Arginase/biosynthesis , Arginine/deficiency , Cells, Cultured , Down-Regulation/immunology , Interleukin-13/physiology , Interleukin-4/physiology , Macrophage Activation , Macrophages, Peritoneal/enzymology , Macrophages, Peritoneal/immunology , Macrophages, Peritoneal/metabolism , Macrophages, Peritoneal/parasitology , Mice , Mice, Inbred C57BL , Mice, Knockout , Nitric Oxide/antagonists & inhibitors , Nitric Oxide Synthase/metabolism , Nitric Oxide Synthase Type II , STAT6 Transcription Factor , Substrate Specificity/immunology , Toxoplasmosis, Animal/enzymology , Toxoplasmosis, Animal/immunology , Toxoplasmosis, Animal/metabolism , Trans-Activators/deficiency , Trans-Activators/geneticsABSTRACT
Jak3-deficient mice display vastly reduced numbers of lymphoid cells. Thymocytes and peripheral T cells from Jak3-deficient mice have a high apoptotic index, suggesting that Jak3 provides survival signals. Here we report that Jak3 regulates T lymphopoiesis at least in part through its selective regulation of Bax and Bcl-2. Jak3-deficient thymocytes express elevated levels of Bax and reduced levels of Bcl-2 relative to those in wild-type littermates. Notably, up-regulation of Bax in Jak3-deficient T cells is physiologically relevant, as Jak3 Bax double-null mice have marked increases in thymocyte and peripheral T-cell numbers. Rescue of T lymphopoiesis by Bax loss was selective, as mice deficient in Jak3 plus p53 or in Jak3 plus Fas remained lymphopenic. However, Bax loss failed to restore proper ratios of peripheral CD4/CD8 T cells, which are abnormally high in Jak3-null mice. Transplantation into Jak3-deficient mice of Jak3-null bone marrow transduced with a Bcl-2-expressing retrovirus also improved peripheral T-cell numbers and restored the ratio of peripheral CD4/CD8 T cells to wild-type levels. The data support the concepts that Jak kinases regulate cell survival through their selective and cell context-dependent regulation of pro- and antiapoptotic Bcl-2 family proteins and that Bax and Bcl-2 play distinct roles in T-cell development.
Subject(s)
Gene Expression Regulation , Protein-Tyrosine Kinases/metabolism , Proto-Oncogene Proteins c-bcl-2/genetics , Proto-Oncogene Proteins/genetics , T-Lymphocytes/cytology , Animals , Apoptosis , CD4-CD8 Ratio , CD8-Positive T-Lymphocytes/cytology , CD8-Positive T-Lymphocytes/metabolism , Cell Differentiation , Cell Survival , Flow Cytometry , Fluorescent Antibody Technique , Gene Deletion , In Situ Nick-End Labeling , Janus Kinase 3 , Mice , Mice, Knockout , Protein-Tyrosine Kinases/deficiency , Protein-Tyrosine Kinases/genetics , Proto-Oncogene Proteins/deficiency , Proto-Oncogene Proteins/metabolism , Proto-Oncogene Proteins c-bcl-2/metabolism , T-Lymphocytes/metabolism , Thymus Gland/cytology , Thymus Gland/growth & development , bcl-2-Associated X ProteinABSTRACT
STAT5 is activated in a broad spectrum of human hematologic malignancies. We addressed whether STAT5 activation is necessary for the myelo- and lymphoproliferative disease induced by TEL/JAK2 using a genetic approach. Whereas mice transplanted with bone marrow transduced with retrovirus expressing TEL/JAK2 develop a rapidly fatal myelo- and lymphoproliferative syndrome, reconstitution with bone marrow derived from Stat5ab-deficient mice expressing TEL/JAK2 did not induce disease. Disease induction in the Stat5a/b-deficient background was rescued with a bicistronic retrovirus encoding TEL/JAK2 and Stat5a. Furthermore, myeloproliferative disease was induced by reconstitution with bone marrow cells expressing a constitutively active mutant, Stat5a, or a single Stat5a target, murine oncostatin M (mOSM). These data define a critical role for Stat5a/b and mOSM in the pathogenesis of TEL/JAK2 disease.
Subject(s)
DNA-Binding Proteins/genetics , Lymphoproliferative Disorders/physiopathology , Milk Proteins , Myeloproliferative Disorders/physiopathology , Oncogene Proteins, Fusion/genetics , Trans-Activators/genetics , Animals , Blotting, Southern , Bone Marrow Cells/pathology , Bone Marrow Transplantation , Colony-Forming Units Assay , DNA, Neoplasm/analysis , Fibrosis , Flow Cytometry , Gene Transfer Techniques , Lymphoproliferative Disorders/genetics , Mice , Mice, Mutant Strains , Mutagenesis/physiology , Myeloproliferative Disorders/genetics , Neoplasm Transplantation , Oncostatin M , Peptides/genetics , Phenotype , Retroviridae/genetics , STAT5 Transcription FactorABSTRACT
The cytokines interleukin 7 (IL-7) and interleukin 4 (IL-4) regulate lymphoid differentiation and function and activate the transcription factor Stat5. Using mice deficient for the 2 highly related transcription factors, Stat5a and Stat5b (Stat5a/b(-/-)), we investigated the role of Stat5 for B-cell differentiation, expansion, and function. Peripheral blood B cells of Stat5-deficient mice are significantly reduced, but no proliferation defects in response to various mitogenic stimuli are found. Also, IgM and IgG1 antibody production and immunoglobulin class switching are not affected. Pre- and pro-B cells of Stat5-deficient animals were found to have reduced responses to IL-7. Pro- and pre-B cells are the target cells of the abl oncogene and numerous studies have suggested that Stat5a/b is essential for transformation by derivatives of the Abelson (abl) gene. To assess the role of Stat5a/b in transformation, we have evaluated the ability of various abl derivatives to transform cells from Stat5a/b-deficient mice in vitro or in vivo. We demonstrate that the absence of Stat5a/b is not essential for the induction of lymphoid or myeloid tumors in vivo or on the ability to transform bone marrow cells in vitro.
Subject(s)
B-Lymphocytes/pathology , B-Lymphocytes/physiology , Cell Transformation, Neoplastic/genetics , DNA-Binding Proteins/genetics , Fusion Proteins, bcr-abl/genetics , Interleukin-7/genetics , Milk Proteins , Trans-Activators/genetics , Animals , Cell Differentiation/drug effects , Cell Differentiation/genetics , Gene Deletion , Gene Expression Regulation, Neoplastic , Genes, abl , Interleukin-7/pharmacology , Mice , STAT5 Transcription FactorABSTRACT
Many receptors activate phospholipase Cgamma1 or -gamma2. To assess the role of PLCgamma2, we derived enzyme-deficient mice. The mice are viable but have decreased mature B cells, a block in pro-B cell differentiation, and B1 B cell deficiency. IgM receptor-induced Ca2+ flux and proliferation to B cell mitogens are absent. IgM, IgG2a, and IgG3 levels are reduced, and T cell-independent antibody production is absent. The similarity to Btk- or Blnk-deficient mice demonstrates that PLCgamma2 is downstream in Btk/Blnk signaling. FcRgamma signaling is also defective, resulting in a loss of collagen-induced platelet aggregation, mast cell FcepsilonR function, and NK cell FcgammaRIII and 2B4 function. The results define a signal transduction pathway broadly utilized by immunoglobulin superfamily receptors.
Subject(s)
B-Lymphocytes/physiology , Isoenzymes/physiology , Receptors, IgG/physiology , Type C Phospholipases/physiology , Adaptor Proteins, Signal Transducing , Agammaglobulinaemia Tyrosine Kinase , Animals , B-Lymphocytes/metabolism , Blood Platelets/physiology , Carrier Proteins/metabolism , Hematopoiesis/physiology , Isoenzymes/genetics , Mice , Mice, Inbred C57BL , Mice, Knockout , Phospholipase C gamma , Phosphoproteins/metabolism , Protein-Tyrosine Kinases/metabolism , Receptors, Antigen, B-Cell/metabolism , Receptors, IgG/metabolism , Type C Phospholipases/geneticsSubject(s)
Genes/physiology , Mice, Knockout , Animals , Fetal Death , Intracellular Signaling Peptides and Proteins , Mice , Mice, Mutant Strains , Mitogen-Activated Protein Kinases/genetics , Mitogen-Activated Protein Kinases/physiology , Phenotype , Protein Serine-Threonine Kinases/metabolism , p38 Mitogen-Activated Protein KinasesABSTRACT
Cytokines induce the tyrosine phosphorylation and associated activation of signal transducers and activators of transcription (Stat). The mechanisms by which this response is terminated are largely unknown. Among a variety of inhibitors examined, the proteasome inhibitors MG132 and lactacystin affected Stat4, Stat5 and Stat6 turnover by significantly stabilizing the tyrosine-phosphorylated form. However, these proteasome inhibitors did not affect downregulation of the tyrosine-phosphorylated Stat1, Stat2 and Stat3. With Stat5 isoforms, we have observed that tyrosine-phosphorylated carboxyl-truncated forms of Stat5 proteins were considerably more stable than phosphorylated wild-type forms of the protein. Also, the C-terminal region of Stat5 could confer proteasome-dependent downregulation to Stat1. With a series of C-terminal deletion mutants, we have defined a relatively small, potentially amphipathic alpha-helical region that is required for the rapid turnover of the phosphorylated Stat5 proteins. The region is also required for transcriptional activation, suggesting that the functions are linked. The results are consistent with a model in which the transcriptional activation domain of activated Stat5 is required for its transcriptional activity and downregulation through a proteasome-dependent pathway.
Subject(s)
Cysteine Endopeptidases/metabolism , DNA-Binding Proteins/metabolism , Milk Proteins , Multienzyme Complexes/metabolism , Protein Structure, Secondary , Trans-Activators/metabolism , Acetylcysteine/analogs & derivatives , Acetylcysteine/pharmacology , Animals , Cell Line , Cysteine Proteinase Inhibitors/pharmacology , Leupeptins/pharmacology , Phosphorylation , Phosphotyrosine/metabolism , Proteasome Endopeptidase Complex , STAT5 Transcription Factor , Transcriptional Activation/drug effects , Tyrosine/metabolismABSTRACT
Stat5 is activated by multiple receptors of hematopoietic cytokines. To study its role during hematopoiesis, we have generated primary chicken myeloblasts expressing different dominant-negative (dn) alleles of Stat5. This caused a striking inability to generate mature cells, due to massive apoptosis during differentiation. Bcl-2 was able to rescue differentiating cells expressing dnStat5 from apoptosis, suggesting that during cytokine-dependent differentiation the main function of the protein is to ensure cell survival. Our findings with dnStat5-expressing chicken myeloblasts were confirmed with primary hematopoietic cells from Stat5a/Stat5b-deficient mice. Bone marrow cells from these animals displayed a strong increase in apoptotic cell death during GM-CSF-dependent functional maturation in vitro. The antiapoptotic protein Bcl-x was induced by GM-CSF and IL-3 in a Stat5-dependent fashion. Ectopic expression of Bcl-x rescued Stat5-deficient bone marrow cells from apoptosis, indicating that Stat5 promotes the survival of myeloid progenitor cells through its ability to induce transcription of the bcl-x gene. Finally, the recruitment of myeloid cells to inflammatory sites was found strongly impeded in Stat5-deficient mice. Taken together, our findings suggest that Stat5 may promote cytokine-dependent survival and proliferation of differentiating myeloid progenitor cells in stress or pathological situations, such as inflammation.
Subject(s)
Apoptosis/physiology , DNA-Binding Proteins/physiology , Hematopoiesis/physiology , Milk Proteins , Trans-Activators/physiology , Alleles , Animals , Apoptosis/genetics , Bone Marrow Cells/physiology , Cell Differentiation/genetics , Cell Differentiation/physiology , Cell Division/genetics , Cell Division/physiology , Cell Line, Transformed , Cell Survival , Cells, Cultured , Chickens , DNA-Binding Proteins/biosynthesis , DNA-Binding Proteins/deficiency , Hematopoiesis/genetics , Inflammation/pathology , Mice , Mice, Inbred C57BL , Mice, Knockout , Proto-Oncogene Proteins c-bcl-2/genetics , Proto-Oncogene Proteins c-bcl-2/physiology , STAT5 Transcription Factor , Trans-Activators/biosynthesis , Trans-Activators/deficiency , bcl-X ProteinABSTRACT
Interleukin 6 (IL-6) is a cytokine produced by immune and nonimmune cells and exhibits functional pleiotropy and redundancy. IL-6 plays an important role in the differentiation of several cell types. Here, we describe a novel function of IL-6: the negative regulation of CD4+ Th1 cell differentiation. While IL-6-directed CD4+ Th2 differentiation is mediated by IL-4, inhibition of Th1 differentiation by IL-6 is independent of IL-4. IL-6 upregulates suppressor of cytokine signaling 1 (SOCS1) expression in activated CD4+ T cells, thereby interfering with signal transducer and activator of transcription 1 (STAT1) phosphorylation induced by interferon gamma (IFNgamma). Inhibition of IFNgamma receptor-mediated signals by IL-6 prevents autoregulation of IFNgamma gene expression by IFNgamma during CD4+ T cell activation, thereby preventing Th1 differentiation. Thus, IL-6 promotes CD4+ Th2 differentiation and inhibits Th1 differentiation by two independent molecular mechanisms.
Subject(s)
Carrier Proteins/metabolism , Interleukin-6/metabolism , Repressor Proteins , Signal Transduction , Th1 Cells/cytology , Animals , Antigen-Presenting Cells/metabolism , Cell Differentiation , DNA-Binding Proteins/metabolism , Gene Expression , Interferon-gamma/genetics , Interferon-gamma/metabolism , Interleukin-12/metabolism , Interleukin-4/biosynthesis , Interleukin-6/pharmacology , Mice , Receptors, Interferon/metabolism , STAT1 Transcription Factor , Suppressor of Cytokine Signaling 1 Protein , Suppressor of Cytokine Signaling Proteins , Th1 Cells/metabolism , Trans-Activators/metabolism , Up-Regulation , Interferon gamma ReceptorABSTRACT
The activation and subsequent proliferation of peripheral T cells requires the engagement of the T cell and a cytokine receptor, typically the IL-2 or IL-4 receptors. Critical to understanding the regulation of peripheral T cells is the knowledge of the unique contributions of each receptor to full T cell activation and cell cycle progression. Mice deficient in Stat5a and Stat5b have demonstrated the essential role that these highly related proteins play in cell cycle progression following peripheral T cell activation. Here we demonstrate that activation of the Stat5 proteins by tyrosine phosphorylation is uniquely contributed by cytokine receptor signaling and specifically does not occur through the T cell receptor complex.
Subject(s)
Cytokines/pharmacology , DNA-Binding Proteins/metabolism , Milk Proteins , T-Lymphocytes/physiology , Trans-Activators/metabolism , Animals , CD3 Complex/immunology , DNA/metabolism , Interleukin-2/pharmacology , Interleukin-4/pharmacology , Mice , Phosphorylation , Receptors, Antigen, T-Cell/physiology , Receptors, Interleukin-2/physiology , Receptors, Interleukin-4/physiology , STAT5 Transcription FactorABSTRACT
SOCS1 is an SH2-containing protein that is primarily expressed in thymocytes in a cytokine- and T cell receptor-independent manner. SOCS1 deletion causes perinatal lethality with death by 2-3 weeks. During this period thymic changes include a loss of cellularity and a switch from predominantly CD4+ CD8+ to single positive cells. Peripheral T cells express activation antigens and proliferate to IL-2 in the absence of anti-CD3. In addition, IFNgamma is present in the serum. Reconstitution of the lymphoid lineage of JAK3-deficient mice with SOCS1-deficient stem cells recapitulates the lethality and T cell alterations. Introducing a RAG2 or IFNgamma deficiency eliminates lethality. The results demonstrate that lymphocytes are critical to SOCS1-associated perinatal lethality and implicate SOCS1 in lymphocyte differentiation or regulation.
Subject(s)
Carrier Proteins/genetics , Carrier Proteins/physiology , Gene Expression Regulation, Developmental , Lymphocytes/physiology , Repressor Proteins , Age Factors , Animals , Animals, Newborn , DNA-Binding Proteins , Dose-Response Relationship, Drug , Flow Cytometry , Interferon-gamma/pharmacology , Janus Kinase 3 , Mice , Mice, Mutant Strains , Protein-Tyrosine Kinases/physiology , Suppressor of Cytokine Signaling 1 Protein , Suppressor of Cytokine Signaling Proteins , T-Lymphocytes/metabolism , Thymus Gland/embryology , Thymus Gland/metabolism , Tissue DistributionABSTRACT
SOCS3 (CIS3/JAB2) is an SH2-containing protein that binds to the activation loop of Janus kinases, inhibiting kinase activity, and thereby suppressing cytokine signaling. During embryonic development, SOCS3 is highly expressed in erythroid lineage cells and is Epo independent. Transgene-mediated expression blocks fetal erythropoiesis, resulting in embryonic lethality. SOCS3 deletion results in an embryonic lethality at 12-16 days associated with marked erythrocytosis. Moreover, the in vitro proliferative capacity of progenitors is greatly increased. SOCS3-deficient fetal liver stem cells can reconstitute hematopoiesis in lethally irradiated adults, indicating that its absence does not disturb bone marrow erythropoiesis. Reconstitution of lymphoid lineages in JAK3-deficient mice also occurs normally. The results demonstrate that SOCS3 is critical in negatively regulating fetal liver hematopoiesis.
Subject(s)
Erythropoiesis/physiology , Gene Expression Regulation, Developmental , Liver/embryology , Proteins/genetics , Proteins/physiology , Repressor Proteins , Transcription Factors , Animals , Dose-Response Relationship, Drug , Flow Cytometry , Hematopoiesis/physiology , In Situ Hybridization , Interleukin-2/pharmacology , Interleukin-4/pharmacology , Liver/physiology , Mice , Mice, Mutant Strains , Models, Genetic , Mutagenesis , Phenotype , Suppressor of Cytokine Signaling 3 Protein , Suppressor of Cytokine Signaling Proteins , Time Factors , TransfectionABSTRACT
Expansion of early lymphoid progenitors requires interleukin-7 (IL-7), which functions through gamma(c)-mediated receptor activation of Jak3. Jak3 deficiency is a cause of severe combined immunodeficiency (SCID) in humans and mice. IL-3 activates many of the same signaling pathways as IL-7, such as Stat5, but achieves this effect through the activation of Jak2 rather than Jak3. We hypothesized that expansion of an IL-7-responsive precursor population through a Jak3-independent pathway using IL-3 may stimulate early lymphoid progenitors and restore lymphopoiesis in Jak3(-/-) mice. Newborn Jak3(-/-) mice that were injected with IL-3 demonstrated thymic enlargement, a 2- to 20-fold increase in thymocyte numbers, and up to a 10-fold expansion in the number of CD4(+), CD8(+), and B220(+)/IgM(+) splenic lymphocytes, consistent with an effect upon an early lymphoid progenitor population. In contrast to control mice, IL-3-treated Jak3(-/-) mice challenged with the allogeneic major histocompatibility complex (MHC) class I-bearing tumor P815 developed a specific CD8-dependent cytotoxic T lymphocyte (CTL) response. IL-3-treated mice also mounted influenza-specific CTL responses and survival was prolonged. The beneficial effects of IL-3 are proposed to be produced by stimulation of a lymphoid precursor population of IL-7Ralpha(+)/IL-3Ralpha(+) cells that we identified in wild-type bone marrow. In vitro, we show that an early IL-7R(+) lymphoid progenitor population expresses IL-3R and proliferates in response to IL-3 and that IL-3 activates Stat5 comparably to IL-7. Clinically, IL-3 may therefore be useful treatment for X-linked and Jak3-deficient SCID patients who lack bone marrow donors.